JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

• Status: Active, not recruiting
• Trial end date: 2033-12-01

Summary

This phase Ib trial studies whether anti-CD19-chimeric antigen receptor (CAR) lentiviral vector-transduced autologous T cells (JCAR014) and durvalumab are safe in combination and can work together in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). JCAR014 is made of each patient's immune cells (T cells) that have a new gene added to them in a laboratory, which programs them to kill lymphoma cells. Durvalumab is a type of drug called a monoclonal antibody, targeted to PD-L1 that may help immune cells attack cancer cells more effectively and thus help JCAR014 work better.

• Phase: Phase 1

Details

• Lead Sponsor: Fred Hutchinson Cancer Research Center
• Collaborators: AstraZeneca; Juno Therapeutics, Inc.; MedImmune LLC; National Cancer Institute (NCI)
• Treatments: Antibodies, Monoclonal; Cyclophosphamide; Durvalumab; Fludarabine; Fludarabine phosphate; Immunoglobulin G; Immunoglobulins